Skip to main content
logo
Mankind Pharma Limited (BOM:543904)
India flag India · Delayed Price · Currency is INR
2,483.60
-17.00 (-0.68%)
At close: Oct 28, 2026

Mankind Pharma Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
22,42619,12919,91019,12912,81914,335
Depreciation & Amortization
8,5978,3885,9403,6973,2081,616
Other Amortization
473.8473.8272.287.351.0749.83
Loss (Gain) From Sale of Assets
-67.123.1-1,614-4.8-16.6537.41
Asset Writedown & Restructuring Costs
206.970.443.5131.6135.6-22.37
Loss (Gain) From Sale of Investments
-939.3-1,262-1,608-1,335-374.31-1,049
Loss (Gain) on Equity Investments
-138.2-116.9-122.4-152.1-124.24-144.48
Stock-Based Compensation
176.8182.4266.4231.90.59-
Provision & Write-off of Bad Debts
384.2200.7136.1139.1137.89115.43
Other Operating Activities
3,4653,0762,290-435.9609.7191.25
Change in Accounts Receivable
-2,836-1,720-1,236-2,899-2,053-659.53
Change in Inventory
-3,734-507.7-2,207-5502,618-5,767
Change in Accounts Payable
3,3662,103-1,460974.6-650.194,198
Change in Other Net Operating Assets
1,6491,1733,4392,2991,753-3,633
Operating Cash Flow
33,03131,21324,13421,52418,1339,198
Operating Cash Flow Growth
14.94%29.33%12.12%18.70%97.15%-19.12%

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-7,641-6,260-4,608-3,153-7,890-4,649
Sale of Property, Plant & Equipment
7929.9119.875.160.4831.46
Cash Acquisitions
---137,027--38.27-
Divestitures
429.2-5,625---
Sale (Purchase) of Intangibles
-947.9-1,113-593.2-670-430.49-18,807
Sale (Purchase) of Real Estate
--79.9---
Investment in Securities
17,4184,8019,013-17,388-2,3669,430
Other Investing Activities
604.8576.9467.7319.4123.57302.84
Investing Cash Flow
9,942-1,964-126,924-20,817-10,541-13,691

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
-39,62465,6223,74610,94712,723
Long-Term Debt Issued
-156.658,891260.938.4558.6
Total Debt Issued
46,89939,780124,5134,00710,98612,782
Short-Term Debt Repaid
--57,485-44,799-3,398-17,642-6,454
Long-Term Debt Repaid
--4,934-6,039-294.5-322.25-104.29
Lease Payments
-289.4-238.8-107.5-25.2-25.54-18.38
Total Debt Repaid
-76,017-62,419-50,838-3,693-17,964-6,558
Net Debt Issued (Repaid)
-29,118-22,63873,675314.4-6,9786,224
Issuance of Common Stock
252.1214.629,632---
Common Dividends Paid
--412.7----
Other Financing Activities
-6,355-6,690-981.3-261.7-419.31-177.86
Financing Cash Flow
-35,222-29,527102,32652.7-7,3976,046

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
109.5156.313.111.723.154.78
Miscellaneous Cash Flow Adjustments
--669.7---
Net Cash Flow
7,861-121.9218.7771.9217.61,557

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
25,39024,95319,52618,37110,2434,549
Free Cash Flow Growth
7.92%27.80%6.29%79.36%125.16%-45.31%
Free Cash Flow Margin
16.51%17.48%16.00%17.90%11.71%5.85%
Free Cash Flow Per Share
61.4160.3748.2545.7925.5711.36
Levered Free Cash Flow
17,28916,7488,69211,9447,117-16,379
Unlevered Free Cash Flow
20,46420,70711,32312,1187,369-16,031
Free Cash Flow After Leases
25,10024,71519,41818,34610,2174,531

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
6,3556,690981.3261.7419.31177.86
Cash Income Tax Paid
6,1395,9275,6684,4153,2314,995
Change in Working Capital
-1,5551,048-1,464-175.71,667-5,861